Biphasic or Mixed
FK228 suppress the growth of human malignant pleural mesothelioma tumor independent to epithelioid or non-epithelioid histology
Molecular Medicine 2024 May 31 [Link] James Mei-Lin Chan, Yuan-Ching Chang, Hua-Chen Chan, Hsiu-Chuan Chan, Wei-Chin Chang, Liu-Fang Wang, Tung-Hu Tsai, Yu-Jen Chen, Wen-Chien Huang Abstract Human malignant pleural mesothelioma (hMPM) is an aggressive, rare disease with a poor prognosis. Histologically, MPM is categorized into epithelioid, biphasic, and sarcomatoid subtypes, with the epithelioid subtype generally…
Read MorePredictive potential of MRI in differentiating the predominant component in biphasic pleural mesothelioma
European Journal of Radiology 2024 May 26 [Link] Ritu R Gill, William G Richards, Hillary Heiling, Emanuele Mazzola, Yin P Hung, Ravi T Seethamraju, Lucian R Chirieac, Raphael Bueno Abstract Purpose: To assess the potential of apparent diffusion coefficient (ADC) values derived from diffusion weighted (DW) MRI preoperatively to predict the predominant histologic component among…
Read MoreDifferential expression of DMD transcripts as a novel prognostic biomarker in histologically diverse mesotheliomas
Translational Lung Cancer Research 2024 April 29 [Link] Nancy Alnassar, Jonathan M J Derry, Giuseppe Luigi Banna, Dariusz C Gorecki Abstract Background: The identification of prognostic biomarkers is crucial for guiding treatment strategies in mesothelioma patients. The Duchenne muscular dystrophy (DMD) gene and its specific transcripts have been associated with patient survival in various tumours.…
Read MoreDiffuse pleural mesotheliomas with genomic near-haploidization: a newly recognized subset with distinct clinical, histologic, and molecular features
Clinical Cancer Research 2024 April 7 [Link] Soo-Ryum Yang, Gowtham Jayakumaran, Jamal Benhamida, Christopher A Febres Aldana, Rachel Fanaroff, Jason Chang, Erika Gedvilaite, Liliana B Villafania, Jennifer L Sauter, Michael Offin, Marjorie G Zauderer, Marc Ladanyi Abstract Purpose: Diffuse pleural mesotheliomas (DPMs) with genomic near-haploidization (GNH) represent a novel subtype first recognized by the TCGA…
Read MoreMethylthioadenosine Phosphorylase and Breast Cancer 1 Protein-Associated Protein 1 as Biomarkers for the Peritoneal Mesothelioma
Cancer Control 2023 January-December [Link] Yue Chen, Xuemei Du, Ying Gao, Heliang Wu, Hongyu Zhao, Yandong Su Abstract Objectives: Combination of Breast Cancer 1 protein-associated protein 1 (BAP1) and methylthioadenosine phosphorylase (MTAP) in the peritoneal mesothelioma (PeM) has yet to be explored. We aim to assess the diagnostic value of combined BAP1 and MTAP to…
Read MoreValidation of a Gene Expression Approach for the Cytological Diagnosis of Epithelioid and Biphasic Pleural Mesothelioma on a Consecutive Series
Cancers 2023 November 22 [Link] Rossella Bruno, Anello Marcello Poma, Greta Alì, Agnese Proietti, Alessandro Ribechini, Antonio Chella, Gabriella Fontanini Abstract Cytological diagnosis of pleural mesothelioma (PM) is controversial, even using ancillary markers (BAP1, MTAP and CDKN2A). Here, we aimed to prospectively validate a previously developed 117-gene expression panel for the differential cytological diagnosis of…
Read MoreBrief Report: Real-world toxicity and survival of combination immunotherapy in pleural mesothelioma – RIOMeso
Journal of Thoracic Oncology 2023 November 15 [Link] N McNamee, C Harvey, L Gray, T Khoo, L Lingam, B Zhang, U Nindra, P Y Yip, A Pal, T Clay, S Arulananda, M Itchins, N Pavlakis, S Kao, S Bowyer, V Chin, L Warburton, I Pires da Silva, T John, B Solomon, M Alexander, A Nagrial…
Read MoreTreatment with tumor-treating fields (TTFields) suppresses intercellular tunneling nanotube formation in vitro and upregulates immuno-oncologic biomarkers in vivo in malignant mesothelioma
eLife 2023 November 13 [Link] Akshat Sarkari, Sophie Korenfeld, Karina Deniz, Katherine Ladner, Phillip Wong, Sanyukta Padmanabhan, Rachel I Vogel, Laura A Sherer, Naomi Courtemanche, Clifford Steer, Kerem Wainer-Katsir, Emil Lou Abstract Disruption of intercellular communication within tumors is emerging as a novel potential strategy for cancer-directed therapy. Tumor-Treating Fields (TTFields) therapy is a treatment…
Read MoreContribution of BAP1 loss and p16 (CDKN2A) deletion analysis to the definitive diagnosis of mesothelioma in effusion cytology
European Review for Medical and Pharmacological Sciences 2023 October [Link] G Aydogdu, S Özekinci Abstract Objective: The cytological diagnosis of mesothelioma is a controversial issue, and definitive diagnosis often requires ancillary tests. The aim of this study was to investigate the contribution of BRCA1-associated protein (1) (BAP1) loss and p16 (CDKN2A) homozygous deletion (HD) on…
Read MorePerioperative discordance in mesothelioma cell type after pleurectomy/decortication-a possible detrimental effect of neoadjuvant chemotherapy due to epithelial to mesenchymal transition?
Interdisciplinary Cardiovascular Thoracic Surgery 2023 November 2 [Link] Luigi Ventura, Michelle Lee, Ralitsa Baranowski, Joanne Hargrave, Michael Sheaff, David Waller Abstract Objectives: The goal was to evaluate the accuracy of preoperative histological assessment and the factors affecting the accuracy and the subsequent effect on postoperative survival after surgical treatment for malignant pleural mesothelioma (MPM). Methods:…
Read More